DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica enrolled the 200th patient in its pivotal Phase 2/3 ReMEDy2 trial of DM199 in acute ischemic stroke, hitting the pre-specified threshold for the trial's interim analysis. An independent DSMB will review the first 200 participants after 90-day follow-up to decide on sample size re-estimation or stopping for futility, with results expected in Q1 2027. DiaMedica remains blinded to the interim data.
Key figures
- Drug Name
- DM199 (rinvecalinase alfa)
- Phase Of Trial
- Phase 2/3
- Clinical sites
- up to 100 globally
- Patients enrolled
- 200
- Planned enrollment min
- 300
- Final sample size range
- 300-728 participants
- Interim analysis timing
- Q1 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.